GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.
PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.
The user is concerned about safely using RU58841 around cats and wonders if applying it 2 hours before a shower is as effective as leaving it overnight. The discussion focuses on the absorption time and effectiveness of RU58841.
Zeuss sublingual products for hair loss, including finasteride and a finasteride-free option, are discussed for their potential to reduce side effects through sublingual delivery. The inclusion of copper peptides is noted, but the high price is a concern without more user feedback.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
A user seeks a topical hair loss treatment without minoxidil, considering options like finasteride, dutasteride, caffeine, tretinoin, or prostaglandin analogues. Recommendations include products like Strut, Maximus, Zeuss, and custom formulas from compounding pharmacies.
The individual has been using minoxidil for beard growth for over two years, started oral minoxidil and dutasteride six months ago, and began RU58841 three months ago, which significantly enhanced their results. They are open to answering questions about their hair loss treatment experience.
A user's update on their hair loss treatments, which included Minoxidil and finasteride; they are experiencing reduced shedding with minimal side effects. Other users provided additional advice to the poster based on their own experiences.
2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.
The conversation discusses using 0.1% Alfatradiol compounded by a pharmacy for hair loss treatment. It also mentions Minoxidil, finasteride, and RU58841 as other treatments.
The user has been using a combination of treatments including Dutasteride, Minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy to address hair loss but continues to experience shedding and density loss. Despite high testosterone and iron levels, the user is frustrated with the lack of improvement and is considering adjusting treatment or exploring other options like a hair transplant.
A 30-year-old man is considering quitting Finasteride due to sexual side effects, including reduced libido and difficulty reaching orgasm, despite its effectiveness in treating hair loss. He is exploring other factors like relationship issues and potential low testosterone, and is considering getting blood work done.
Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.
The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
Ursolic acid, found in apple peels, lemongrass, rosemary, and lavender, may have anti-androgen effects similar to finasteride. It might be beneficial for hair health when used with other treatments like Minoxidil, Finasteride, and RU58841.
The user has been using RU58841 with minoxidil for hair loss, which helped but caused itchiness, and is considering increasing the dose and adding topical finasteride to the treatment. They are inquiring if they can mix RU58841 and finasteride into one solution with Stemoxydine or if they need separate solutions and which to apply first.
RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.
PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.
The conversation is about considering switching from Fluridil to Pyrilutamide for hair loss treatment. Pyrilutamide is suggested to be more effective, with a recommendation to use the 1% variant twice daily.
A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
PP405 is discussed as a potential hair loss treatment, with doubts about its effectiveness and availability. Users mention using finasteride and minoxidil, and express concerns about PP405's cost and market release.